INTRODUCTION
============

Cervical cancer is the fourth most common cancer affecting women worldwide, with an estimated 528,000 new cases and 266,000 deaths annually.^[@b1]^ Approximately 85% of these new cases and 87% of deaths occur in low- and middle-income countries (LMICs).^[@b1]^ Because of limited screening programs and high HIV prevalence, cervical cancer is the leading cause of cancer death in Botswana.^[@b2]^

More than 75% of patients with cervical cancer in Botswana have locally advanced disease.^[@b3]^ In Botswana, current treatment includes radiotherapy and cisplatin-based chemotherapy. Radiotherapy, however, is not available in the public sector; hence, patients are referred to the private sector for radiation. On the basis of our pilot data, the median time from diagnosis to treatment is 108 days.^[@b3]^ To decrease cervical cancer morbidity and mortality, it is imperative to identify and address factors contributing to delays.

Cancer management requires action from a range of expert providers over a prolonged time.^[@b4]^ Difficulties in communication and coordination among these various providers can cause cancer care to become fragmented, ultimately contributing to treatment delays and worse outcomes,^[@b5],[@b6]^ which are a potential cause of delay in cervical cancer care in Botswana. Studies in developed countries in which surgeons, pathologists, oncologists, radiologists, social workers or psychologists, and nurses are involved in discussing each case^[@b7]^ suggest that multidisciplinary teams (MDTs) can decrease time to diagnosis, time to treatment, and duplication of investigations, as well as improve accuracy of diagnosis.^[@b8]^ Thus, the establishment of an MDT is warranted.

Actionable knowledge about scaling MDTs into LMICs remains sparse. Results from an international survey showed that breast cancer MDT clinics across the world used different models and lacked standard guidelines.^[@b9]^ In several developing countries, cancer centers do not have formal MDTs.^[@b10]^ Another survey in Arab countries revealed that only 49% of respondents reported having MDTs.^[@b11]^ This could be because establishing MDT clinics in LMICs is difficult because of competing health-care demands, limited health-care personnel, and poor infrastructure.^[@b12],[@b13]^ Although there are established oncology MDT clinics in LMICs in Africa, such as in Uganda and Egypt, there have been no published studies on the direct benefits of these MDT clinics.^[@b14],[@b15]^

The purpose of this paper is to describe the implementation and early outcomes of a gynecologic MDT clinic in Botswana, which, to our knowledge, is the first gynecologic MDT clinic in an LMIC. We also describe the impact of the MDT clinic on reducing treatment delay.

METHODS
=======

Organization Before Weekly Meeting
----------------------------------

Through a collaborative effort across providers, we established a weekly gynecologic MDT clinic at Botswana's national referral facility in Gaborone. A nurse coordinator was assigned to manage patient flow. All new referrals with basic information, including stage, date of biopsy, results of biopsy specimen assessment, and HIV status, were sent to the nurse coordinator, who then procures patient records and ensures that biopsy results are available. All patients to be discussed were contacted by the coordinator the day before the clinic meeting.

Workflow During Weekly Meeting
------------------------------

At the beginning of each clinic meeting, a team composed of a radiation oncologist, clinical oncologist, gynecologist, pathologist, nurse coordinator, and palliative care specialist discuss all patients referred to the MDT clinic. Together, an oncologist and gynecologist examine patients and determine an appropriate care plan. If the patient requires radiation, paperwork to document sponsorship of treatment by the government of Botswana is completed and submitted to the referral office. Investigations for staging or treatment planning are ordered if they have not been done previously. If patients are HIV positive or untested, they are referred to an HIV clinic for antiretroviral treatment evaluation or retesting for HIV. Patients are then counseled on the treatment plan by an oncologist, gynecologist, and palliative care doctor, and given a follow-up date in 2 weeks to make sure all the investigations are completed and all submitted documents are processed.

We evaluated the patient characteristics and radiation treatment delays in patients seen in this clinic. The Wilcoxon rank-sum test was used to compare the delay in treatment before and after MDT clinic initiation. Only data up to September 2015 were assessed for treatment delays, because the radiation department in Botswana closed in September 2015 for an upgrade and patients were referred to South Africa.

RESULTS
=======

A gynecologic MDT clinic was initiated at Princess Marina Hospital in May 2015. Between May and December 2015, 135 patients were seen in this clinic, with an average of 28 patients per month. Most patients (n = 82; 60%) were HIV positive, 31% (n = 42) were HIV negative, and the HIV status of 11 patients was unknown. The most common diagnosis of patients who came to the MDT clinic was cervical cancer (60%), followed by high-grade preinvasion, or cervical intraepithelial neoplasia 3, lesions (12%) and vulvar cancer (11%). Forty-two percent of patients (n = 57) had locally advanced cancer and needed chemoradiation. Further details of patients seen in the clinic are listed in [Table 1](#tbl1){ref-type="table"}. Sixty-two percent of patients (n = 83) needed only one visit for care coordination. Treatment delays were evaluated for radiation treatment as well as surgery. The median delay from date of biopsy to start of radiation treatment was 39 days (interquartile range \[IQR\], 34 to 57 days) after MDT initiation, compared with 108 days (IQR, 71 to 147 days; *P* \< .001) before MDT initiation. The median delay from clinic visit to the start of radiation treatment was 24 days (IQR, 19 to 31 days) and median delay from clinic visit to surgery was 31 days (IQR, 13 to 43 days) after MDT initiation ([Table 2](#tbl2){ref-type="table"}).
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DISCUSSION
==========

The complexity of cancer care makes it vulnerable to delay and suboptimal outcomes. By enhancing communication and streamlining care, MDTs are important in reducing treatment delays and improving patient outcomes. The results from the establishment of a gynecologic MDT clinic in Botswana are promising. The time from diagnosis to the start of radiation treatment was reduced by greater than 50% following initiation of the MDT clinic. Furthermore, only 38.5% of patients needed more than one clinic visit, suggesting that even one visit to the MDT clinic was sufficient to facilitate patient navigation through the system.

Similar MDT models are also being piloted for head and neck, palliative care, and breast cancer in Botswana. A follow-up clinic is being piloted where all patients treated with gynecologic cancer are seen after treatment or followed up until signs of toxicities or recurrence appear. All the patients seen in the MDT clinic will be linked to the follow-up clinic and will receive regular reminders for a visit or a telephone call for follow-up.

In summary, establishment of an MDT clinic in LMIC settings is feasible. It can help with care coordination and reducing delays, and can be used more broadly as a model of cancer care for all cancers in Botswana and other LMICs.
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